Skip to main content
Article thumbnail
Location of Repository

Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members

By NiCole Finch, Matt Baker, Richard Crook, Katie Swanson, Karen Kuntz, Rebecca Surtees, Gina Bisceglio, Anne Rovelet-Lecrux, Bradley Boeve, Ronald C. Petersen, Dennis W. Dickson, Steven G. Younkin, Vincent Deramecourt, Julia Crook, Neill R. Graff-Radford and Rosa Rademakers

Abstract

Mutations in the progranulin gene (GRN) are an important cause of frontotemporal lobar degeneration (FTLD) with ubiquitin and TAR DNA-binding protein 43 (TDP43)-positive pathology. The clinical presentation associated with GRN mutations is heterogeneous and may include clinical probable Alzheimer's disease. All GRN mutations identified thus far cause disease through a uniform disease mechanism, i.e. the loss of functional GRN or haploinsufficiency. To determine if expression of GRN in plasma could predict GRN mutation status and could be used as a biological marker, we optimized a GRN ELISA and studied plasma samples of a consecutive clinical FTLD series of 219 patients, 70 control individuals, 72 early-onset probable Alzheimer's disease patients and nine symptomatic and 18 asymptomatic relatives of GRN mutation families. All FTLD patients with GRN loss-of-function mutations showed significantly reduced levels of GRN in plasma to about one third of the levels observed in non-GRN carriers and control individuals (P < 0.001). No overlap in distributions of GRN levels was observed between the eight GRN loss-of-function mutation carriers (range: 53–94 ng/ml) and 191 non-GRN mutation carriers (range: 115–386 ng/ml). Similar low levels of GRN were identified in asymptomatic GRN mutation carriers. Importantly, ELISA analyses also identified one probable Alzheimer's disease patient (1.4%) carrying a loss-of-function mutation in GRN. Biochemical analyses further showed that the GRN ELISA only detects full-length GRN, no intermediate granulin fragments. This study demonstrates that using a GRN ELISA in plasma, pathogenic GRN mutations can be accurately detected in symptomatic and asymptomatic carriers. The ∼75% reduction in full-length GRN, suggests an unbalanced GRN metabolism in loss-of-function mutation carriers whereby more GRN is processed into granulins. We propose that plasma GRN levels could be used as a reliable and inexpensive tool to identify all GRN mutation carriers in early-onset dementia populations and asymptomatic at-risk individuals

Topics: Original Articles
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2664450
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). 29 [Epub ahead of print].
    2. (2008). A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.
    3. (2008). A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging
    4. (2007). Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol
    5. (1998). Association of missense and 50-splice-site mutations in tau with the inherited dementia FTDP-17. Nature
    6. (2001). Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on Frontotemporal Dementia and Pick’s disease. Arch Neurol
    7. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s Disease. Neurology
    8. (2002). Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell
    9. (2008). Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol Dis
    10. (2006). Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol
    11. (2007). Frontotemporal dementia. Semin Neurol
    12. (2004). Frontotemporal lobar degeneration and ubiquitin immunohistochemistry.
    13. (2004). Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration.
    14. (1998). Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology
    15. (2008). Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol
    16. (2008). Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology
    17. (2008). Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum Mutat
    18. (1998). Granulins: the structure and function of an emerging family of growth factors.
    19. (2006). HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol
    20. (2009). Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology
    21. (2008). Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat
    22. (2008). Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol
    23. (2006). Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet
    24. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature
    25. (2006). Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain
    26. (2007). Neurol Clin
    27. (2007). Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.
    28. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature
    29. (2007). Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C–4T (Arg493X) mutation: an international initiative. Lancet Neurol
    30. (2009). Plasma progranulin levels in FTD and Alzheimer’s disease Brain
    31. (2003). Progranulin (granulin-epithelin precursor, PC-cellderived growth factor, acrogranin) mediates tissue repair and tumorigenesis.
    32. (2008). Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.
    33. (2003). Progranulin is a mediator of the wound response. Nat Med
    34. (2008). Progranulin locus deletion in frontotemporal dementia. Hum Mutat
    35. (2007). Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol
    36. (2007). Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat
    37. (2007). Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging
    38. (2007). The genetics of frontotemporal lobar degeneration. Curr Neurol Neurosci Rep
    39. (2008). The logopenic/phonological variant of primary progressive aphasia. Neurology
    40. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.